Full Press Release Details
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and
next steps on enabling study initiation
The FDA advised the Company to submit pivotal Part B trial protocol and associated
statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and
registration; IND amendment submission expected in Q2 2025
High dose and low dose of
TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of
April 10, 2025, data cutoff
Program update on pivotal trial design, Rett syndrome natural history data analysis and clinical
data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in Q2 2025 in conjunction with IRSF Rett Syndrome Scientific Meeting
Conference call and live webcast today at 8:30 AM Eastern Time
Dallas May 15, 2025 Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology
company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2025, and provided a
We are pleased with the significant regulatory and clinical progress across our TSHA-102
program in clinical evaluation for children, adolescents and adults suffering from Rett syndrome. We believe our interactions with the U.S. FDA under the RMAT mechanism have consistently been productive and continue to support a clear path to
registration, said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. Importantly, we reached alignment with the FDA on key elements of the pivotal Part B trial design for TSHA-102 and
next steps on enabling study initiation. Subsequently, the FDA advised us to proceed directly to submitting our pivotal trial protocol and associated statistical analysis plan as an amendment to the IND application, which we expect to submit in the
current quarter. By eliminating the need for a formal end-of-phase meeting, this approach may expedite study initiation and registration.
Mr. Nolan continued, We believe the progress we ve made with the FDA on our registrational pathway supports the strength of our data-driven
approach and further enables our goal to bring TSHA-102 to patients with this devastating disease as expeditiously as possible. We anticipate providing a fulsome regulatory update and clinical data from our
two REVEAL trials in conjunction with the annual IRSF Rett Syndrome Scientific Meeting in the current quarter.
Recent Corporate and TSHA-102 Program Highlights
Anticipated Milestones
First Quarter 2025 Financial Highlights
Research and Development Expenses: Research and development expenses were $15.6 million for the three months ended March 31, 2025, compared to
$20.7 million for the three months ended March 31, 2024. The $5.1 million decrease was driven by Good Manufacturing Practices batch activities with the intended commercial manufacturing process for
TSHA-102 performed during the three months ended March 31, 2024. The decrease in expenses was partially offset by higher compensation expenses for R&D employees as a result of increased headcount.
General and Administrative Expenses: General and administrative expenses were $8.2 million for the three months ended March 31,
2025, compared to $7.1 million for the three months ended March 31, 2024. The increase of $1.1 million was primarily due to higher compensation expenses and increases in legal and professional fees.
Net Loss: Net loss for the three months ended March 31, 2025, was $21.5 million, or $0.08 per share, compared to a net loss of
$24.1 million, or $0.10 per share, for the three months ended March 31, 2024.
Cash and Cash Equivalents: As of March 31, 2025,
Taysha had $116.6 million in cash and cash equivalents. The Company continues to expect that its current cash resources will support planned operating expenses and capital requirements into the fourth quarter of 2026.
Conference Call and Webcast Information
Taysha management will hold a conference call and webcast today at 8:30 AM ET to review its financial and operating results and provide a corporate
update. The dial-in number for the conference call is 877-407-0792 (U.S./Canada) or 201-689-8263 (international). The conference ID for all callers is 13753490. The live webcast and replay may be accessed by visiting Taysha s website.
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment,
TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel
miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of
overexpression. TSHA-102 has received Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European
Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the
X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of
communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with
early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently,
there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in
the U.S., EU, and U.K.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for
severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies
that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The
Company s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly
translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as
anticipates, believes, expects, intends, projects, plans, and future or similar expressions are intended to identify forward-looking statements.
Forward-looking statements include statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results
initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, and our other product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our
research, development and regulatory plans for our product candidates, including the timing of initiating additional trials and reporting data from our clinical trials, advice from the FDA on the regulatory pathway for
TSHA-102, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and our current cash resources supporting our planned operating
expenses and capital requirements into the fourth quarter of 2026. Forward-looking statements are based on management s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially
and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these
forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ( SEC ) filings, including in our Annual Report on Form 10-K for the
full-year ended December 31, 2024, which is available on the SEC s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak
only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 2,302 | $ | 3,411 | ||||
| Operating expenses: | ||||||||
| Research and development | 15,565 | 20,657 | ||||||
| General and administrative | 8,158 | 7,084 | ||||||
| Total operating expenses | 23,723 | 27,741 | ||||||
| Loss from operations | (21,421 | ) | (24,330 | ) | ||||
| Other income (expense): | ||||||||
| Change in fair value of warrant liability | 102 | (337 | ) | |||||
| Change in fair value of term loan | (1,530 | ) | (1,053 | ) | ||||
| Interest income | 1,326 | 1,693 | ||||||
| Interest expense | (19 | ) | (29 | ) | ||||
| Other income (expense) | 13 | (5 | ) | |||||
| Total other income (expense), net | (108 | ) | 269 | |||||
| Net loss | $ | (21,529 | ) | $ | (24,061 | ) | ||
| Net loss per common share, basic and diluted | $ | (0.08 | ) | $ | (0.10 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 269,306,331 | 231,249,344 |
Taysha Gene Therapies, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands, except share and per share data)
| March 31, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 116,593 | $ | 139,036 | ||||
| Restricted cash | 449 | 449 | ||||||
| Prepaid expenses and other current assets | 3,666 | 2,645 | ||||||
| Total current assets | 120,708 | 142,130 | ||||||
| Restricted cash | 2,151 | 2,151 | ||||||
| Property, plant and equipment, net | 7,236 | 7,485 | ||||||
| Operating lease right-of-use assets | 8,079 | 8,381 | ||||||
| Other non-current assets | 188 | 217 | ||||||
| Total assets | $ | 138,362 | $ | 160,364 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,326 | $ | 3,592 | ||||
| Accrued expenses and other current liabilities | 10,761 | 12,862 | ||||||
| Deferred revenue | 7,470 | 9,773 | ||||||
| Total current liabilities | 22,557 | 26,227 | ||||||
| Term loan, net | 42,453 | 43,942 | ||||||
| Operating lease liability, net of current portion | 17,093 | 17,361 | ||||||
| Other non-current liabilities | 1,200 | 1,309 | ||||||
| Total liabilities | 83,303 | 88,839 | ||||||
| Stockholders equity | ||||||||
| Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2025 and December 31, 2024 | ||||||||
| Common stock, $0.00001 par value per share; 400,000,000 shares authorized and 205,054,570 and 204,943,306 issued and outstanding as of March 31, 2025 and December 31 2024, respectively | 2 | 2 | ||||||
| Additional paid-in capital | 681,177 | 677,859 | ||||||
| Accumulated other comprehensive loss | (2,286 | ) | (4,031 | ) | ||||
| Accumulated deficit | (623,834 | ) | (602,305 | ) | ||||
| Total stockholders equity | 55,059 | 71,525 | ||||||
| Total liabilities and stockholders equity | $ | 138,362 | $ | 160,364 |
Senior Director, Corporate Communications and
Taysha Gene Therapies, Inc.